(SeaPRwire) – By: Christian Brooks
Healthcare stocks have lagged the market for years. Now, investors are shifting from AI to defensive sectors. This rotation plus AI adoption in drug development is reviving the sector.
The Health Care Select Sector SPDR Fund closed up 3% Thursday, breaking short-term resistance. The S&P 500’s healthcare component is down 4% year to date, with 4% earnings growth—the lowest of any sector. But AI is changing drug screening: companies now evaluate 5-50x more early-stage molecules. Eli Lilly leads with GLP-1 drugs (22B free cash this year, 47B by 2030). Intuitive Surgical’s new da Vinci platform, Natera’s doubling revenue, Edwards Lifesciences’ new therapies are key picks. UnitedHealth and Eli Lilly top Quant Rankings at 3.47 and 3.44.
The sector won’t boom uniformly. Investors should focus on firms with AI integration and clear growth paths. Eli Lilly, Intuitive Surgical, and Edwards Lifesciences are solid long-term bets.
Author bio: Christian Brooks, a prominent financial commentator covering global market trends and sector rotation strategies.